{
  "id": 6202511,
  "title": "Could ‘friendly’ bacteria help fight pancreatic cancer?",
  "url": "https://urgent.news/2026/09/08/could-friendly-bacteria-help-fight-pancreatic-cancer-6202511",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-09-08T00:30:00.000Z",
  "source": {
    "name": "Free Malaysia Today",
    "slug": "free-malaysia-today-freemalays",
    "url": "https://www.freemalaysiatoday.com/category/leisure/2026/09/08/could-friendly-bacteria-help-fight-pancreatic-cancer"
  },
  "original_language": "en",
  "account": "Pancreatic cancer is notoriously difficult to treat due to its ability to suppress the immune system. US researchers are investigating a novel method by transforming probiotic bacteria into microscopic drug factories that can infiltrate tumors and release treatment from within. The study, published in Science Advances, utilized an engineered form of Bifidobacterium longum, a bacterium commonly found in the gut and often associated with probiotics. Scientists modified these bacteria to carry and release interleukin-2 (IL-2), an immune-stimulating molecule, directly into pancreatic tumors. In animal studies, this approach diminished tumor growth and bolstered the immune system's ability to attack cancer cells. The method proved even more effective when combined with chemotherapy, radiation, or immunotherapy. One reason this technique is promising is Bifidobacterium's preference for oxygen-depleted environments. Many solid tumors, such as pancreatic tumors, contain low-oxygen regions, while healthy tissues have higher oxygen levels. This characteristic enables the engineered bacteria to survive and function within a tumor while being rapidly eliminated from healthy body parts. Once inside, they act as tiny delivery vehicles, delivering the immune-stimulating treatment precisely where it is most needed, rather than exposing the entire body to high levels of it. The engineered bacteria utilize a modified version of IL-2 called SumIL-2, which is designed to favor cancer-fighting T cells while minimizing unwanted immune reactions. In animal models, the engineered bacteria primarily gathered inside the tumors, enhancing the activity of CD8+ T cells, immune cells that can directly attack cancer. As a result, tumor growth slowed. The researchers also tested the bacterial treatment alongside existing cancer therapies, and when paired with chemotherapy, radiation, or anti-PD-L1 immunotherapy, the combination controlled tumors better and improved survival compared to the individual treatments. While these findings are still experimental, the treatment has not been tested in humans, and researchers must study its long-term safety, potential systemic effects, and the durability of the immune response. Additionally, they aim to explore whether the bacteria could be administered orally instead of via injection and whether this strategy could complement newer pancreatic cancer drugs. This research falls within the broader field of \"bugs as drugs,\" where scientists engineer bacteria to deliver medicines to precise areas of the body.",
  "summary": "Scientists have engineered a common probiotic bacterium to carry an immune-boosting treatment directly into pancreatic tumours.",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Free Malaysia Today",
        "title": "Could ‘friendly’ bacteria help fight pancreatic cancer?",
        "url": "https://urgent.news/2026/09/08/could-friendly-bacteria-help-fight-pancreatic-cancer",
        "published": "2026-09-08T00:30:00.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}